Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Wayne Pisano is Director at Altimmune. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 13, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
1 buy, median −26.3 pts vs S&P 500, beat it 0 of 1 time.
Average −26.3 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Feb 13, 2026 to Feb 13, 2026, measured from the first close after the filing. Past results, not a forecast.
2 purchases disclosed; 0% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $379 today ($1K put in); the same in the S&P 500 (SPY): $1.1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
AltimmuneALT
Nov 13, 2026Bought~$16K
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
As of the latest filing on , Wayne Pisano reported holding 492,414 shares of Oncolytics Biotech (ONCY), worth about $182K at the last close of $0 (Nov 13, 2026). Holdings are also on file at Altimmune (ALT); together they are worth about $279K. In the last 12 months, Wayne Pisano bought $16K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Oncolytics Biotech ONCY | 492,414 | 492K direct | $0 | $182K | Feb 12, 2026 |
| Altimmune ALT | 58,800 | 59K direct | $2 | $97K | Nov 13, 2026 |
Is this Wayne Pisano’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Wayne Pisano bought shares on the open market in 2018 and 2026. Sales in 2 of the 9 years since 2018.
Wayne Pisano reported 2 open-market purchases and 2 sales since 2018; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $16K1×1 trade | — |
| 2022 | — | $300K1×1 trade |
| 2020 | — | $102K1×1 trade |
| 2018 | $9.2K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Feb 12, 2026, Wayne Pisano reported holding 492,414 shares of Oncolytics Biotech (ONCY). At the last close of $0 on Nov 13, 2026, that is about $182K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Wayne Pisano reported 1 open-market purchase worth $16K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Wayne Pisano bought shares on the open market in 2018 and 2026. Sales in 2 of the 9 years since 2018.
In SEC filings since 2018: the latest open-market purchase is from 2026; the latest open-market sale is from 2022.
Altimmune (ALT), from 2018 to 2026: 2 purchases and 2 sales.
Wayne Pisano reported 2 open-market purchases and 2 sales here, 2018 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
